Nutra Pharma Corp (NPHC)

[Goofy R]

RPI-78M: TOTAL JOKE--HERE'S WHY!!

NPHC (RPI-78M) = BANKRUPTCY!!! RIK'S-CRIMINALS/FRAUD:

ALL BELOW:

MASSIVE DEBT
ZERO EARNINGS
SEC FRAUD CASE
FDA WARNINGS
RIK'S CRIMINAL/FRAUD PAST

HERE'S THE PATHETIC LOW-DOWN ON RPI-78M!!NOTHING!!!!
THEY'VE HAD RPI-78M ORPHAN STATUS FOR 4 YEARS!!

RIK KEEPS LYING AND GIVING FALSE HOPE ON A PHASE 2, WHICH A) HE CAN'T AFFORD TO DO, AND B) HE WON'T RELEASE THE ACTUAL RESULTS FROM PHASE 1... SO THERE IS NOTHING THERE!!!!! IF THERE WAS SOMETHING THERE TO WORK WITH, HE'D EASILY BE ABLE TO GET INVESTORS TO HELP WITH THE FINANCING OF IT!!

AND MOST IMPORTANTLY, IT'S ORPHAN DRUG STATUS, WHICH MEANS IT WILL NEVER MAKE ANY SERIOUS MONEY ANYWAYS... ONLY IF IT CAN BE SPRING-BOARDED TO NEW MORE PROFITABLE DRUGS -- HE CAN'T AFFORD THAT!!!

RPI-78M in clinical trials
Link: https://multiplesclerosisnewstoday.com/rpi-78m

RPI-78M was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) to treat MS in children on Sept. 8, 2015. Orphan drug status is granted to therapies that may not be lucrative to pharmaceutical companies, but are highly beneficial for people with rare diseases.

The company has completed Phase 1 clinical trials for RPI-78M, but these results have not been published. The company states that the treatment was well-tolerated and aims to move the potential drug to Phase 2 clinical trials soon.

In September 2016, Nutra Pharma announced a partnership with Omnia Biologics to prepare for the upcoming clinical trials. Omnia Biologics will clone and purify the alpha-cobratoxin gene required to produce RPI-78M. Nutra Pharma has announced a similar collaboration on May 31, 2017, with the University of Maryland’s Bioprocess Scale-up Facility (BSF), which will aim to optimize the sustainable production of RPI-78M at high quality, using the cloned gene.

BALANCE SHEET/RIK'S CRIMINALS/FRAUD/LITIGATION!!! PROOF!

Notice the NET LOSS of $4,028,748!! (Balance Sheet Below)
HENCE... THEY HAVE ZERO EARNINGS AND REVENUE!!! IF YOU THINK THAT $120,000 OF REVENUES IS GOOD...

ALL RIK DID FOR US, WAS LIE TO US, AS HE HAS BEEN DOING TO ALL SHAREHOLDERS FOR OVER 15 YEARS!! HERE'S PROOF BELOW!!

FACT: HERE IS A SHORT LIST OF RIK'S CRIMINAL "FRIENDS" HE'S HIRED ALONG WITH A SMALL LIST OF HIS LITIGATION MESSES, WITH LINKS:

PHIL PICCOLO:

http://worldwidescam.com/sumphil.htm

http://patrickpretty.com/2014/04/27/mlm-watchdog-phil-piccolo-is-scamming-again/

SEAN PETER McMANUS:

https://structuredsettlements.typepad.com/structured_settlements_4r/2019/01/patriot-settlement-resources-mcmanus-sued-by-finra-for-selling-snake-oil-without-a-license.html

Waiora Lawsuit against Rik (Fake Ingredients/Fraud):

http://aprilmarietucker.com/wp-content/uploads/2013/05/Stanley-J.-Cherelstein-Waiora-lawsuit.pdf

https://www.law360.com/articles/922469/health-co-barred-from-selling-supplement-in-ip-row

Tommy Edward Crutchfield (Snake Guy in the video):

https://www.justice.gov/archive/opa/pr/1999/April/140enr.htm

Dr. Keith Gordon, DMV (Pet Pain Away Spokesperson):

https://www.mycentraljersey.com/story/news/local/middlesex-county/2015/12/28/fancy-pups-avenel-closed-owner-arrested/77981976/

COMPLAINT FOR PATENT INFRINGEMENT, BREACH OF LICENSE AGREEMENT, FRAUD AND RELATED CLAIMS (JURY DEMAND ENDORSED HEREON):

https://insight.rpxcorp.com/litigation_documents/2326309

Excerpt:

Rik’s FRAUD!!!:

22. Although Deitsch and NDA arranged to begin manufacture and sale of Product, they refused to inform Plaintiff, on later inquiries, of any manufacturing details, including the identity of the manufacturer. Case: 5:07-cv-00785-JG Doc #: 1 Filed: 03/16/07 8 of 16. PageID #: 62
-9-23.
Shortly after entering into the Agreement, NDA claimed to encounter problems with its marketing efforts in Germany. In a June 30, 2004, e-mail from his “nutrapharma” e-mail address, Deitsch informed Plaintiff of problems with “the German group” and the manufacturing of the Product.
Plaintiff now believes that no “German Division of MRI Labs” was available to NDA and that Deitsch misrepresented his German marketing infrastructure to induce Plaintiff to enter into the Agreement.

BALANCE SHEET:

NUTRA PHARMA CORP.
Consolidated Statements of Operations


For the Years Ended
December 31, 2017 2016
Net sales $ 120,979 168,356
Cost of sales 26,903 38,965
Impairment of inventory - 184,039
Gross profit 94,076 (54,648)

Operating expenses:
Selling, general and administrative - including stock based compensation of $73,576 and $390,608 for the years ended December 31, 2017 and 2016, respectively 1,476,016 1,988,868
Total operating expenses 1,476,016 1,988,868
LOSS FROM OPERATIONS $(1,381,940) (2,043,516)

Other (income) expenses
Rental income - 19,381
Interest expense (358,651) (293,785)
Change in fair value of derivatives (2,273,968) (1,258,649)
Gain (Loss) on settlement of indebtedness, net (14,189) 128,956
Other expenses (2,646,808) (1,404,097)
Net loss before income taxes (4,028,748) (3,447,613)
Provision for income taxes - -
NET LOSS $(4,028,748) (3,447,613)